What question did this study set out to answer?

This research aims to investigate the dual roles of tumor-infiltrating B cells in head and neck cancers and their potential as therapeutic targets.

April 23, 2026

The role of tumor-infiltrating B cells in the development and pathogenesis of head and neck cancers: Implications for therapeutic approach

Key Points

This research aims to investigate the dual roles of tumor-infiltrating B cells in head and neck cancers and their potential as therapeutic targets.
Analyzed the role of tumor-infiltrating B cells within the tumor microenvironment of head and neck cancers.
Explored interactions between TIBs and other immune cells, particularly in relation to immunotherapy responses.
Reviewed literature on prognostic and predictive implications of TIB infiltration in various head and neck cancer types.
Higher infiltration of tumor-infiltrating B cells correlates with improved survival in patients receiving immune checkpoint inhibitors.
Tertiary lymphoid structures formed by B cells are linked to stronger antitumor immune responses.
Regulatory B cells in tumors contribute to conditions that promote tumor growth.

Abstract

Head and neck cancers (HNCs) pose a significant global health challenge, with treatment complexities and profound impacts on patient quality of life. Tumor-infiltrating B cells (TIBs) within the tumor microenvironment (TME) are emerging as critical yet dual regulators of HNC immunity, exhibiting both pro- and anti-tumorigenic properties. This manuscript explores the prognostic and predictive roles of TIBs across diverse HNCs, including squamous cell carcinomas and lymphomas. TIBs enhance antitumor immunity through antibody production, antigen presentation, and the formation of tertiary lymphoid structures (TLSs), which correlate with improved survival and response to immune checkpoint inhibitors (ICIs). Conversely, regulatory B cells contribute to immunosuppression, promoting tumor progression. Notably, high TIB infiltration, particularly within TLSs, is associated with superior outcomes in ICI-treated patients, highlighting their potential as biomarkers and therapeutic targets. However, challenges such as data variability and limited study scales underscore the need for further investigation into TIB subpopulations and their molecular dynamics. Future research should prioritize understanding TIB interactions with other immune cells and developing novel immunotherapies, including genetic engineering and oncolytic viruses, to advance HNC treatment and optimize patient outcomes.

اسأل الذكاء الاصطناعي

Bookmark